Search Results - "Koch, Hans Friedrich"

New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies by Foucher, Christelle, Aubonnet, Patrick, Reichert, Petr, Berli, Mario, Schaeffer, Axel, Calvo Vargas, Cesar Gonzalo, Lochocka, Anna, Belenky, Dmitry, Koch, Hans-Friedrich

“…Guidelines propose additional therapy to statin to treat elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDLC) in dyslipidemic…”
Get more information

Prognostic factors for long-term survival after adult liver transplantation by Filali Bouami, Soufiane, Gwiasda, Jill, Beneke, Jan, Kaltenborn, Alexander, Liersch, Sebastian, Suero, Eduardo M., Koch, Hans-Friedrich, Krauth, Christian, Klempnauer, Jürgen, Schrem, Harald

“…Purpose Prognostic factors for survival ≥ 15 years and life years lost after liver transplantation are largely unknown. Methods One thousand six hundred thirty…”
Get full text

Statistical approach to quality assessment in liver transplantation by Schrem, Harald, Volz, Sophia, Koch, Hans-Friedrich, Gwiasda, Jill, Kürsch, Priscila, Goldis, Alon, Pöhnert, Daniel, Winny, Markus, Klempnauer, Jürgen, Kaltenborn, Alexander

“…Purpose This study investigated the utility of retrospective two one-sided cumulative sum (CUSUM) charts combined with multivariable regression analysis in…”
Get full text

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial by Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Waller, Cornelius F.

“…Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or…”
Get full text

Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation by Rausch, Lisa, Koenecke, Christian, Koch, Hans-Friedrich, Kaltenborn, Alexander, Emmanouilidis, Nikos, Pape, Lars, Lehner, Frank, Arelin, Viktor, Baumann, Ulrich, Schrem, Harald

“…Post-transplant lymphoproliferative disorder (PTLD) adversely affects patients' long-term outcome. The paired t test and McNemar's test were applied in a…”
Get full text

Risk Balancing of Cold Ischemic Time against Night Shift Surgery Possibly Reduces Rates of Reoperation and Perioperative Graft Loss by Schrem, Harald, Koch, Hans Friedrich, Lehner, Frank, Kaltenborn, Alexander, Ringe, Bastian P., Boeckler, Julius, Emmanouilidis, Nikos, Klempnauer, Juergen

“…Background. This retrospective cohort study evaluates the advantages of risk balancing between prolonged cold ischemic time (CIT) and late night surgery…”
Get full text

Exact unconditional distributions for dichotomous data in many-to-one comparisons by Koch, Hans-Friedrich, Hothorn, Ludwig A.

“…The exact conditional distribution of a statistic for the many-to-one design with dichotomous response variables was firstly given by Williams (1988). His…”
Get full text

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer by Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Mukhametshina, Guzel, Nemsadze, Gia, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Baramidze, Kakhaber, Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Mamillapalli, Gopichand, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Fuentes-Alburo, Adolfo, Waller, Cornelius F.

“…Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate…”
Get full text